Multidisciplinary Rehabilitation Has Redefined Pediatric Short Bowel Syndrome Care
Short bowel syndrome after intestinal resection remains the leading cause of intestinal failure in children, but management no longer hinges on prolonged parenteral support alone. Over the past decade, survival, growth, and the chance of achieving enteral autonomy have improved as intestinal rehabilitation programs have become more organized and more protocol driven. The modern approach blends nutrition, pharmacology, and surgery in a sequence tailored to the child’s residual anatomy and adaptive capacity.
Pediatric SBS is fundamentally a problem of insufficient absorptive surface, but the downstream consequences extend far beyond calories and fluid balance. Long-term parenteral support can preserve life, yet it also carries the burden of intestinal failure-associated liver disease, catheter-related bloodstream infections, and the practical constraints of chronic central access. In children, those risks collide with growth, neurodevelopment, and family function, which is why the field has moved toward strategies that reduce dependence on intravenous nutrition rather than merely maintaining it.
The review synthesized primary clinical studies on management strategies and clinically relevant outcomes in pediatric SBS secondary to intestinal resection, using a PRISMA-based search of PubMed and Embase. Because the available evidence was clinically and methodologically heterogeneous, the findings were brought together qualitatively rather than through pooled effect estimates. That matters because the pediatric SBS population is not a single disease state; anatomy, remaining bowel length, ileocecal valve status, colon continuity, and underlying diagnosis all shape the trajectory toward adaptation or persistent intestinal failure.
Early structured care now sits at the center of management. Multidisciplinary intestinal rehabilitation programs bring together nutrition support, surgery, pharmacy, hepatology, and feeding specialists in a coordinated model that can adjust therapy as bowel function evolves. In practice, this framework does more than organize care. It creates the conditions for intestinal adaptation by promoting enteral stimulation, reducing avoidable parenteral exposure, and identifying children who are failing to progress before complications become entrenched.
Enteral feeding remains biologically central. Careful advancement of feeds encourages mucosal adaptation, supports gut hormone signaling, and helps the intestine recover function after resection. A slow, deliberate transition from parenteral dependence to enteral feeding can reduce complications tied to central lines and liver injury while giving the bowel the physiologic stimulus it needs to adapt. The timing and composition of feeds are individualized, but the principle is consistent: the gut must be used if it is to recover.
Pharmacologic therapy has also moved forward, especially with glucagon-like peptide-2 analogs. These agents have reduced parenteral support requirements and are now a meaningful part of the rehabilitation pathway. Their clinical value is easy to understand at the bedside: by enhancing intestinal absorption and supporting adaptation, they can shift a child closer to autonomy without immediate reliance on reconstruction or transplantation. Their place in therapy reflects a broader change in the field, where medical management is no longer passive support but an active attempt to reshape intestinal function.
The surgical landscape has narrowed in a deliberate way. As rehabilitation programs have improved outcomes, the need for intestinal transplantation has decreased, and the role of autologous bowel reconstruction has become more selective. Procedures such as Serial Transverse Enteroplasty and Longitudinal Intestinal Lengthening and Tailoring are now reserved for carefully chosen patients, particularly those with persistent bowel dilatation, dysmotility, and inadequate adaptation despite optimized medical and nutritional care. Surgery is no longer the default response to short bowel anatomy; it is an escalation reserved for a subset with anatomy that can be meaningfully remodeled.
The sequence of care is clinically important. A child with dilated, poorly propulsive bowel may benefit from lengthening procedures if optimized nutrition and medical therapy fail, but operating too early can expose the patient to risk before the intestine has had time to adapt on its own. On the other hand, waiting too long may allow chronic parenteral exposure, cholestasis, and recurrent line infection to accumulate. The review points to a management model in which the decision to operate depends on residual anatomy, functional trajectory, and response to rehabilitation rather than on a fixed timeline.
One of the most consequential shifts in pediatric SBS is the greater emphasis on predictors of enteral autonomy. Achieving full enteral independence is not simply a matter of surviving the initial resection. It depends on the amount and quality of remaining bowel, the ability to tolerate progressive feeds, and the degree to which rehabilitation can reduce dependence on intravenous support. The review makes clear that prognosis has improved because clinicians now intervene earlier, monitor adaptation more systematically, and use nutrition, medication, and surgery as complementary tools rather than competing strategies.
The broader implication is concrete. Children with SBS secondary to intestinal resection are increasingly managed in centers that can coordinate long-term rehabilitation, recognize complications early, and select surgical candidates with precision. This is not a cosmetic refinement in care delivery; it directly affects the likelihood of avoiding chronic liver disease, repeated bloodstream infections, and transplant evaluation.
Where Pediatric Intestinal Failure Still Needs Better Evidence
Even with these advances, the evidence base remains incomplete. The review calls for prospective pediatric studies with standardized outcome measures to define the best timing and sequencing of nutrition, pharmacologic therapy, and surgery. Current practice is built on improving but still heterogeneous data, which makes it hard to compare strategies across centers or to decide when a child should move from medical rehabilitation to reconstructive surgery.
A more precise evidence base would help answer practical bedside questions: which infants and children are most likely to reach enteral autonomy, when GLP-2 analogs should be introduced relative to feed advancement, and which anatomical patterns justify early reconstruction. Until those questions are answered prospectively, pediatric SBS care will continue to rely on multidisciplinary judgment, close physiologic monitoring, and a willingness to adjust therapy as the bowel adapts.